Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by LPL Financial LLC

LPL Financial LLC lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 11.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 73,308 shares of the company’s stock after acquiring an additional 7,452 shares during the quarter. LPL Financial LLC’s holdings in Roivant Sciences were worth $867,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ROIV. Nordea Investment Management AB lifted its holdings in shares of Roivant Sciences by 22.5% in the 4th quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after buying an additional 52,031 shares during the period. Barclays PLC boosted its position in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Retirement Systems of Alabama grew its stake in shares of Roivant Sciences by 26.9% during the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock worth $6,116,000 after purchasing an additional 112,286 shares during the period. Elevate Capital Advisors LLC purchased a new position in shares of Roivant Sciences during the 4th quarter valued at approximately $2,116,000. Finally, Thompson Siegel & Walmsley LLC lifted its stake in shares of Roivant Sciences by 10.1% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company’s stock valued at $6,688,000 after purchasing an additional 51,705 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $10.04 on Tuesday. The stock has a market capitalization of $7.16 billion, a PE ratio of -66.93 and a beta of 1.25. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The company has a fifty day moving average of $10.32 and a two-hundred day moving average of $11.16.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Monday.

Insider Activity

In other news, CAO Rakhi Kumar sold 227,500 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Eric Venker sold 315,522 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the sale, the chief operating officer now directly owns 959,457 shares of the company’s stock, valued at approximately $10,611,594.42. This represents a 24.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,295,541 shares of company stock worth $13,900,538 over the last quarter. 7.90% of the stock is currently owned by corporate insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.